Mindfulness and pharmacological prophylaxis have comparable effect on biomarkers of inflammation and clinical indexes in chronic migraine with medication overuse: results at 12 months after withdrawal.
Author: Grazzi L1, D'Amico D2, Raggi A3, Leonardi M3, Ciusani E4, Corsini E4, D'Andrea G5, Bolner A5, Salgado-García F6, Andrasik F6, Sansone E2
Affiliation:
1Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy. licia.grazzi@istituto-besta.it.
2Headache and Neuroalgology Unit, Neurological Institute "C. Besta" IRCCS Foundation, Via Celoria 11, 20133, Milan, Italy.
3Neurology, Public Health and Disability Unit, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy.
4Laboratory of Clinical Pathology and Medical Genetic, Neurological Institute "C. Besta" IRCCS Foundation, Milan, Italy.
5Research & Innovation (R&I), Padua, Italy.
6Department of Psychology, University of Memphis, Memphis, TN, USA.
Conference/Journal: Neurol Sci.
Date published: 2017 May
Other:
Volume ID: 38 , Issue ID: Suppl 1 , Pages: 173-175 , Special Notes: doi: 10.1007/s10072-017-2874-0. , Word Count: 137
Chronic migraine (CM) is a disabling condition arising from a complex mixture of interconnected biological, psychological and social factors, and is often associated with medication overuse (MO). Mindfulness is emerging as a helpful treatment for pain, and one study showed that the longitudinal 12 months' course of CM-MO patients that attended mindfulness-based treatment alone was similar to that of patients receiving medical prophylaxis alone; in this study, we describe the course of biomarkers of inflammation. Our results provide initial evidence of sustained similar effects on reduced concentration of biomarkers of inflammation, although not sizeable enough to reach statistical significance. Whether more intensive treatment and/or larger samples would lead to greater changes is unknown, but these encouraging preliminary findings suggest further research is warranted.
KEYWORDS: Biomarkers; Chronic migraine; Interleukin-6; Medication overuse; Mindfulness
PMID: 28527073 DOI: 10.1007/s10072-017-2874-0
BACK
